Onkologie. 2023:17(4):261-266 | DOI: 10.36290/xon.2023.050
Cemiplimab: monotherapy and combination therapy of NSCLC - analysis of locally advanced disease
- Pneumologická klinika, 1. LF UK a Fakultní Thomayerova nemocnice, Praha
Patients with unresectable locally advanced NSCLC who are not candidates for concurrent chemoradiation have been excluded from trials with immunotherapy. Trials with cemiplimab are exception. Trials EMPOWER-Lung 1 (first-line cemiplimab monotherapy) and EMPOWER-Lung 3 (first-line cemiplimab with chemotherapy) were not only focused on metastatic stage but also included patients mentioned above.
Keywords: NSCLC (Non-Small-Cell Lung Cancer), locally advanced stage, EMPOWER-Lung 1, EMPOWER-Lung 3, immunotherapy, cemiplimab.
Accepted: October 3, 2023; Published: October 5, 2023 Show citation
References
- ESMO guidelines for lung and chest tumours, dostupné z: www.esmo.org/guidelines/lung-and-chest-tumours/early-stage-and-locally-advanced-non-metastatic-non-small-cell-lung-cancer/eupdate-early-and-locally-advanced-non-small-cell-lung-cancer-nsclc-treatment-recommendations2.
- Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377(20):1919-1929.
Go to original source... 
Go to PubMed... - Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021;397(10274):592-604. Go to original source... Go to PubMed...
- Gogishvili M, Melkadze T, Makharadze T, et al. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. Nat Med. 2022;28(11):2374-2380. Go to original source... Go to PubMed...
- Kalinka E, Bondarenko I, Gogishvili M, et al. 114M0 First-line cemiplimab for locally advanced non-small cell lung cancer: Updated subgroup analyses from EMPOWER-Lung 1 and EMPOWER-Lung 3. Journal of Thoracic Oncology. 2023;18:S106. 10.1016/S1556-0864(23)00369-6. Go to original source...
- European Medicines Agency. LIBTAYO: Summary of product characteristics, 2023 [online]. Available from: https://www.ema.europa.eu/en/documents/product-information/libtayo-epar-product-information_en.pdf.